VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Participants and their families not planning to    │ Participants and their families not planning to    │     100 │
│ move away from the area for the duration of the    │ move away from the area for the duration of the    │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants able and willing to comply with all   │ Participants able and willing to comply with all   │     100 │
│ aspects of the study, including a standardized,    │ aspects of the study, including a standardized,    │         │
│ reduced calorie diet and an age appropriate,       │ reduced calorie diet and an age appropriate,       │         │
│ increased physical activity program                │ increased physical activity program                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants considered in stable health in the    │ Participants considered in stable health in the    │     100 │
│ opinion of the investigator                        │ opinion of the investigator                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able and willing to support and supervise study    │ Able and willing to support and supervise study    │     100 │
│ participation in the opinion of the investigator,  │ participation in the opinion of the investigator,  │         │
│ including consideration of any existing physical,  │ including consideration of any existing physical,  │         │
│ medical, or mental condition that prevents         │ medical, or mental condition that prevents         │         │
│ compliance with the protocol                       │ compliance with the protocol                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able and willing to personally comply with and     │ Able and willing to personally comply with and     │     100 │
│ execute all aspects of the study requirements for  │ execute all aspects of the study requirements for  │         │
│ the caregivers or guardians                        │ the caregivers or guardians                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant new illness within 1 month  │ Clinically significant new illness within 1 month  │     100 │
│ before randomization that may affect the           │ before randomization that may affect the           │         │
│ participant's ability to fulfill the study         │ participant's ability to fulfill the study         │         │
│ requirements or significantly confound the         │ requirements or significantly confound the         │         │
│ assessments                                        │ assessments                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants who cannot swallow investigational    │ Participants who cannot swallow investigational    │     100 │
│ products                                           │ products                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants with T2DM who have hypoglycemia       │ Participants with T2DM who have hypoglycemia       │     100 │
│ unawareness                                        │ unawareness                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Aortic regurgitation mild or greater               │ Aortic regurgitation mild or greater               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mitral regurgitation moderate or greater           │ Mitral regurgitation moderate or greater           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systolic pulmonary artery pressure (SPAP) \>40     │ Systolic pulmonary artery pressure (SPAP) >40 mmHg │     100 │
│ mmHg (and/or tricuspid regurgitation \[TR\] jet    │ (and/or tricuspid regurgitation [TR] jet velocity  │         │
│ velocity \>2.9 m/s) In cases where an actual SPAP  │ >2.9 m/s) In cases where an actual SPAP value is   │         │
│ value is not measurable due to lack of adequate TR │ not measurable due to lack of adequate TR jet, the │         │
│ jet, the pulmonary flow acceleration time measured │ pulmonary flow acceleration time measured at the   │         │
│ at the right ventricular outflow tract (RVOTAT)    │ right ventricular outflow tract (RVOTAT) will be   │         │
│ will be used to assess eligibility. Participants   │ used to assess eligibility. Participants with a    │         │
│ with a RVOTAT ≤100 milliseconds (msec) will be     │ RVOTAT =100 milliseconds (msec) will be excluded,  │         │
│ excluded, suggesting an elevated mean SPAP;        │ suggesting an elevated mean SPAP; eligibility for  │         │
│ eligibility for the those participants with RVOTAT │ the those participants with RVOTAT between 100 and │         │
│ between 100 and 120 msec will be determined based  │ 120 msec will be determined based on combined      │         │
│ on combined assessment of the TR jet, septal       │ assessment of the TR jet, septal motion, and right │         │
│ motion, and right ventricular size                 │ ventricular size                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intracardiac mass, tumor, or thrombus              │ Intracardiac mass, tumor, or thrombus              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of congenital heart disease               │ Evidence of congenital heart disease               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant pericardial effusion (eg,   │ Clinically significant pericardial effusion (eg,   │     100 │
│ moderate or larger or with hemodynamic compromise) │ moderate or larger or with hemodynamic compromise) │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant renal or hepatic disease as evidenced  │ Significant renal or hepatic disease as evidenced  │     100 │
│ by a serum creatinine greater than 1.5× upper      │ by a serum creatinine greater than 1.5× upper      │         │
│ limit of normal (ULN), serum transaminases greater │ limit of normal (ULN), serum transaminases greater │         │
│ than 3× ULN, or total bilirubin greater than 1.5×  │ than 3× ULN, or total bilirubin greater than 1.5×  │         │
│ ULN in absence of Gilbert's syndrome               │ ULN in absence of Gilbert's syndrome               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any suicidal ideation with intent with or without  │ Any suicidal ideation with intent with or without  │     100 │
│ a plan, at the time of or within 6 months of       │ a plan, at the time of or within 6 months of       │         │
│ Screening, as indicated by answering "Yes" to      │ Screening, as indicated by answering "Yes" to      │         │
│ questions 4 or 5 on the Suicidal Ideation section  │ questions 4 or 5 on the Suicidal Ideation section  │         │
│ of the Columbia-Suicide Severity Rating Scale      │ of the Columbia-Suicide Severity Rating Scale      │         │
│ (C-SSRS)                                           │ (C-SSRS)                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any suicidal behavior in the past based on the     │ Any suicidal behavior in the past based on the     │     100 │
│ C-SSRS                                             │ C-SSRS                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any history of anorexia or bulimia within 2 years  │ Any history of anorexia or bulimia within 2 years  │     100 │
│ before Screening, Attention Deficit Hyperactivity  │ before Screening, Attention Deficit Hyperactivity  │         │
│ Disorder, any Diagnostic and Statistical Manual of │ Disorder, any Diagnostic and Statistical Manual of │         │
│ Mental Disorders, 5th Edition depressive disorder, │ Mental Disorders, 5th Edition depressive disorder, │         │
│ bipolar disorder, or schizophrenia                 │ bipolar disorder, or schizophrenia                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known secondary causes (genetic, endocrine, or     │ Known secondary causes (genetic, endocrine, or     │     100 │
│ metabolic) for obesity (eg, Prader-Willi syndrome, │ metabolic) for obesity (eg, Prader-Willi syndrome, │         │
│ Bardet Biedl syndrome, Down's Syndrome, untreated  │ Bardet Biedl syndrome, Down's Syndrome, untreated  │         │
│ hypothyroidism, Cushing's syndrome, daily systemic │ hypothyroidism, Cushing's syndrome, daily systemic │         │
│ corticosteroid exposure for longer than 30 days,   │ corticosteroid exposure for longer than 30 days,   │         │
│ history of significant exposure to corticosteroids │ history of significant exposure to corticosteroids │         │
│ for chronic illness during the past year; inhaled  │ for chronic illness during the past year; inhaled  │         │
│ steroids will be allowed)                          │ steroids will be allowed)                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of other products intended for weight loss     │ Use of other products intended for weight loss     │     100 │
│ including prescription drugs, over-the-counter     │ including prescription drugs, over-the-counter     │         │
│ (OTC) drugs, and herbal preparations within 1      │ (OTC) drugs, and herbal preparations within 1      │         │
│ month before Screening                             │ month before Screening                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ selective serotonin reuptake inhibitors            │ selective serotonin reuptake inhibitors            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ serotonin norepinephrine reuptake inhibitors       │ serotonin norepinephrine reuptake inhibitors       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ tricyclic antidepressants                          │ tricyclic antidepressants                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ bupropion                                          │ bupropion                                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ triptans                                           │ triptans                                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ St. John's Wort                                    │ St. John's Wort                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ tryptophan                                         │ tryptophan                                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ linezolid                                          │ linezolid                                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ dextromethorphan in any form (eg, OTC cold         │ dextromethorphan in any form (eg, OTC cold         │     100 │
│ medicines)                                         │ medicines)                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ lithium                                            │ lithium                                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ tramadol                                           │ tramadol                                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ antipsychotics or other dopamine antagonists       │ antipsychotics or other dopamine antagonists       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ antiseizure medications including valproic acid,   │ antiseizure medications including valproic acid,   │     100 │
│ zonisamide, topiramate, and lamotrigine            │ zonisamide, topiramate, and lamotrigine            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ oral steroids (topical and inhaled steroids are    │ oral steroids (topical and inhaled steroids are    │     100 │
│ acceptable)                                        │ acceptable)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ stimulant medications (eg, Ritalin, Concerta,      │ stimulant medications (eg, Ritalin, Concerta,      │     100 │
│ Biphetamine, and Dexedrine)                        │ Biphetamine, and Dexedrine)                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ benzodiazepines                                    │ benzodiazepines                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of drugs known to increase the risk for        │ Use of drugs known to increase the risk for        │     100 │
│ cardiac valvulopathy within 6 months before        │ cardiac valvulopathy within 6 months before        │         │
│ Screening, including but not limited to pergolide, │ Screening, including but not limited to pergolide, │         │
│ ergotamine, methysergide, and cabergoline          │ ergotamine, methysergide, and cabergoline          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History or evidence of clinically significant      │ History or evidence of clinically significant      │     100 │
│ disease (eg, malignancy; cardiac, respiratory,     │ disease (eg, malignancy; cardiac, respiratory,     │         │
│ gastrointestinal, renal, or psychiatric disease)   │ gastrointestinal, renal, or psychiatric disease)   │         │
│ other than prediabetes (impaired fasting glucose   │ other than prediabetes (impaired fasting glucose   │         │
│ or impaired glucose tolerance), type 2 diabetes    │ or impaired glucose tolerance), type 2 diabetes    │         │
│ treated with oral anti-diabetic agents (excluding  │ treated with oral anti-diabetic agents (excluding  │         │
│ sulfonylurea) or non-insulin injectable            │ sulfonylurea) or non-insulin injectable            │         │
│ antidiabetic agents, obstructive sleep apnea,      │ antidiabetic agents, obstructive sleep apnea,      │         │
│ dyslipidemia, and nonalcoholic fatty liver disease │ dyslipidemia, and nonalcoholic fatty liver disease │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of Belviq XR within 6 months before Screening  │ Use of Belviq XR within 6 months before Screening  │     100 │
│ or hypersensitivity to Belviq XR or any of the     │ or hypersensitivity to Belviq XR or any of the     │         │
│ excipients                                         │ excipients                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant change in diet or level of physical    │ Significant change in diet or level of physical    │     100 │
│ activity within 1 month before dosing or change in │ activity within 1 month before dosing or change in │         │
│ weight of more than 5 kg within 3 months before    │ weight of more than 5 kg within 3 months before    │         │
│ Screening                                          │ Screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any use of a very-low-calorie (\<1000              │ Any use of a very-low-calorie (<1000 calories/day) │     100 │
│ calories/day) weight loss diet within 6 months     │ weight loss diet within 6 months before Screening  │         │
│ before Screening                                   │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of alcohol or drug dependence or abuse     │ History of alcohol or drug dependence or abuse     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Recreational drug use within 2 years before        │ Recreational drug use within 2 years before        │     100 │
│ Screening                                          │ Screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known to be human immunodeficiency virus positive  │ Known to be human immunodeficiency virus positive  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known to have active viral hepatitis (B or C)      │ Known to have active viral hepatitis (B or C)      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Malignancy within 5 years before Screening         │ Malignancy within 5 years before Screening         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unable to attend scheduled visits (eg, lack of     │ Unable to attend scheduled visits (eg, lack of     │     100 │
│ transportation) or lack of a caregiver or guardian │ transportation) or lack of a caregiver or guardian │         │
│ to supervise study participation                   │ to supervise study participation                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ongoing epilepsy or other seizure disorder, or use │ Ongoing epilepsy or other seizure disorder, or use │     100 │
│ of medications for a seizure disorder within 6     │ of medications for a seizure disorder within 6     │         │
│ months of screening or any time between screening  │ months of screening or any time between screening  │         │
│ and randomization                                  │ and randomization                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants with a blood pressure in the 95th     │ Participants with a blood pressure in the 95th     │     100 │
│ percentile or greater for age, sex, and height on  │ percentile or greater for age, sex, and height on  │         │
│ 2 separate readings recorded on 2 separate days.   │ 2 separate readings recorded on 2 separate days.   │         │
│ Those participants who had uncontrolled            │ Those participants who had uncontrolled            │         │
│ hypertension at Screening can be rescreened more   │ hypertension at Screening can be rescreened more   │         │
│ than 1 month after initiation or adjustment of     │ than 1 month after initiation or adjustment of     │         │
│ antihypertensive therapy 1 time                    │ antihypertensive therapy 1 time                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Currently enrolled in another clinical study or    │ Currently enrolled in another clinical study or    │     100 │
│ has used any investigational drug or device within │ has used any investigational drug or device within │         │
│ 30 days before providing informed consent          │ 30 days before providing informed consent          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Planned bariatric surgery during the study or      │ Planned bariatric surgery during the study or      │     100 │
│ prior bariatric surgical procedures                │ prior bariatric surgical procedures                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Not suitable to participate in the study in the    │ Not suitable to participate in the study in the    │     100 │
│ opinion of the investigator, including             │ opinion of the investigator, including             │         │
│ consideration of any existing physical, medical,   │ consideration of any existing physical, medical,   │         │
│ or mental condition that prevents compliance with  │ or mental condition that prevents compliance with  │         │
│ the protocol                                       │ the protocol                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Had unprotected sexual intercourse within 30 days  │ Had unprotected sexual intercourse within 30 days  │     100 │
│ before study entry and who do not agree to use a   │ before study entry and who do not agree to use a   │         │
│ highly effective method of contraception (eg,      │ highly effective method of contraception (eg,      │         │
│ total abstinence, an intrauterine device, a        │ total abstinence, an intrauterine device, a        │         │
│ double-barrier method \[such as condom plus        │ double-barrier method [such as condom plus         │         │
│ diaphragm with spermicide\], a contraceptive       │ diaphragm with spermicide], a contraceptive        │         │
│ implant, an oral contraceptive, or have a          │ implant, an oral contraceptive, or have a          │         │
│ vasectomized partner with confirmed azoospermia)   │ vasectomized partner with confirmed azoospermia)   │         │
│ throughout the entire study period and for 28 days │ throughout the entire study period and for 28 days │         │
│ after study drug discontinuation                   │ after study drug discontinuation                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Are currently abstinent and do not agree to use a  │ Are currently abstinent and do not agree to use a  │     100 │
│ double-barrier method (as described above) or      │ double-barrier method (as described above) or      │         │
│ refrain from sexual activity during the study      │ refrain from sexual activity during the study      │         │
│ period and for 28 days after study drug            │ period and for 28 days after study drug            │         │
│ discontinuation                                    │ discontinuation                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Are using hormonal contraceptives, but are not on  │ Are using hormonal contraceptives, but are not on  │     100 │
│ a stable dose of the same hormonal contraceptive   │ a stable dose of the same hormonal contraceptive   │         │
│ product for at least 4 weeks before dosing and who │ product for at least 4 weeks before dosing and who │         │
│ do not agree to use the same contraceptive during  │ do not agree to use the same contraceptive during  │         │
│ the study and for 28 days after study drug         │ the study and for 28 days after study drug         │         │
│ discontinuation (Note: All female participants     │ discontinuation (Note: All female participants     │         │
│ will be considered to be of childbearing potential │ will be considered to be of childbearing potential │         │
│ unless they have been sterilized surgically \[ie,  │ unless they have been sterilized surgically [ie,   │         │
│ bilateral tubal ligation, total hysterectomy, or   │ bilateral tubal ligation, total hysterectomy, or   │         │
│ bilateral oophorectomy, all with surgery at least  │ bilateral oophorectomy, all with surgery at least  │         │
│ 1 month before dosing\])                           │ 1 month before dosing])                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HbA1c ≥6.5%                                        │ HbA1c =6.5%                                        │      91 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Healthy male or female adolescents, age 12 to 17   │ Healthy male or female adolescents, age 12 to 17   │      97 │
│ years (inclusive) at Screening, with a BMI that is │ years (inclusive) at Screening, with a body mass   │         │
│ greater than or equal to the United States-        │ index (BMI) that is greater than or equal to the   │         │
│ weighted mean of the 95th percentile based on age  │ United States-weighted mean of the 95th percentile │         │
│ and sex with a body weight greater than 60         │ based on age and sex with a body weight greater    │         │
│ kilograms (kg). Participants with Type 2 diabetes  │ than 60 kilograms (kg). Participants with Type 2   │         │
│ mellitus (T2DM) may have a pre-existing or new     │ diabetes mellitus (T2DM) may have a pre-existing   │         │
│ diagnosis of T2DM                                  │ or new diagnosis of T2DM                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ fasting plasma glucose (FPG) ≥126 mg/dL (7.0       │ fasting plasma glucose (FPG) =126 mg/dL (7.0       │      98 │
│ mmol/L)                                            │ mmol/L)                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mitral or aortic valve stenosis greater than mild  │ Mitral or aortic valve stenosis greater than mild  │      98 │
│ (ie, aortic stenosis: jet \>3.0 meters per second  │ (ie, aortic stenosis: jet >3.0 meters per second   │         │
│ \[m/s\], mean gradient \>25 millimeters of mercury │ [m/s], mean gradient >25 millimeters of mercury    │         │
│ \[mmHg\], and aortic valve area \<1.5 centimeters  │ [mmHg], and aortic valve area <1.5 centimeters     │         │
│ squared \[cm\^2\]; mitral stenosis: mean gradient  │ squared [cm^2]; mitral stenosis: mean gradient >5  │         │
│ \>5 mmHg and mitral valve area \<1.5 cm\^2)        │ mmHg and mitral valve area <1.5 cm^2)              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Left ventricular ejection fraction \<45%           │ Left ventricular ejection fraction <45%            │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Special needs participants who are unable to       │ Special needs participants who are unable to       │      99 │
│ comprehend study-related instructions (eg, mild to │ comprehend study-related instructions (eg, mild to │         │
│ profound mental retardation \[intelligence         │ profound mental retardation [intelligence quotient │         │
│ quotient \<70\], moderate to severe cognitive      │ <70], moderate to severe cognitive developmental   │         │
│ developmental delay, pervasive development         │ delay, pervasive development disorders, autism)    │         │
│ disorders, autism)                                 │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female participants who are breastfeeding or       │ Female participants who are breastfeeding or       │      99 │
│ pregnant at Screening or Baseline (as documented   │ pregnant at Screening or Baseline (as documented   │         │
│ by a positive β-human chorionic gonadotropin       │ by a positive beta-human chorionic gonadotropin    │         │
│ test). A separate Baseline assessment is required  │ test). A separate Baseline assessment is required  │         │
│ if a negative screening pregnancy test was         │ if a negative screening pregnancy test was         │         │
│ obtained more than 72 hours before the first dose  │ obtained more than 72 hours before the first dose  │         │
│ of study drug                                      │ of study drug                                      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) by  │ Are using hormonal contraceptives, but are not on  │      41 │
│ an oral glucose tolerance test (OGTT) All T2DM     │ a stable dose of the same hormonal contraceptive   │         │
│ participants must have an HbA1c \<10% at           │ product for at least 4 weeks before dosing and who │         │
│ Screening. If participants are being or need to be │ do not agree to use the same contraceptive during  │         │
│ treated with antidiabetic agents, the T2DM         │ the study and for 28 days after study drug         │         │
│ treatment regimen must be stable for at least 3    │ discontinuation (Note: All female participants     │         │
│ months before randomization. A single rescreen is  │ will be considered to be of childbearing potential │         │
│ allowed following stabilization. Stable control    │ unless they have been sterilized surgically [ie,   │         │
│ refers to minimal dose changes to existing         │ bilateral tubal ligation, total hysterectomy, or   │         │
│ medications for glycemic control and no            │ bilateral oophorectomy, all with surgery at least  │         │
│ medications being initiated for glycemic control   │ 1 month before dosing])                            │         │
│ in the 3 months before randomization. Minimal      │                                                    │         │
│ changes are defined as a change without any change │                                                    │         │
│ in dose frequency, no add-on or discontinuation of │                                                    │         │
│ other antidiabetic agents and the participant has  │                                                    │         │
│ not been hospitalized due to hypo- or              │                                                    │         │
│ hyperglycemic events                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 12 Years                  │ Mitral regurgitation moderate or greater           │      41 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 17 Years                  │ Mitral regurgitation moderate or greater           │      41 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any of the following findings on Screening         │ Malignancy within 5 years before Screening         │      42 │
│ echocardiography                                   │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants with a new diagnosis of T2DM (ie,     │ Participants with a blood pressure in the 95th     │      43 │
│ diagnosed at Screening) should be based on the     │ percentile or greater for age, sex, and height on  │         │
│ 2016 American Diabetes Association (ADA)           │ 2 separate readings recorded on 2 separate days.   │         │
│ guidelines. The diagnostic criteria are met if a   │ Those participants who had uncontrolled            │         │
│ participant has unequivocal hyperglycemia (random  │ hypertension at Screening can be rescreened more   │         │
│ plasma glucose ≥200 milligrams per deciliter       │ than 1 month after initiation or adjustment of     │         │
│ (mg/dL) (11.1 millimoles per liter \[mmol/L\])     │ antihypertensive therapy 1 time                    │         │
│ with classic symptoms of hyperglycemia or          │                                                    │         │
│ hyperglycemic crisis) OR any of the following      │                                                    │         │
│ criteria are observed and confirmed                │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Others                                             │ triptans                                           │      43 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Caregivers or guardians meet the following         │ Mitral regurgitation moderate or greater           │      44 │
│ requirements                                       │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants with pre-existing T2DM should have    │ Participants and their families not planning to    │      45 │
│ prior documentation consistent with the diagnosis  │ move away from the area for the duration of the    │         │
│ and/or be on active pharmacotherapy for T2DM       │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serotonergic drugs within 7 days (or 5 half-lives, │ Currently enrolled in another clinical study or    │      47 │
│ whichever is longer) or monoamine oxidase          │ has used any investigational drug or device within │         │
│ inhibitors within 30 days before Randomization,    │ 30 days before providing informed consent          │         │
│ including                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any of the following medications            │ Participants who cannot swallow investigational    │      48 │
│                                                    │ products                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female participants of childbearing potential who  │ Participants who cannot swallow investigational    │      50 │
│                                                    │ products                                           │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 90
Average Levenshtein Ratio of individual lines: 91.31506849315069
OverAll Ratio: 90.65753424657535
